The AlphaLISA® immunoassay kit for human PTEN enables the detection and quantitation of human PTEN in tissue homogenates and cell lysates using a homogeneous AlphaLISA assay (no wash steps). Other species of PTEN were not tested, but detection is expected with mouse and rat PTEN due to >99% sequence homology.
For research use only; not for diagnostic procedures. All products to be used in accordance with applicable laws and regulations including without limitation, consumption & disposal requirements under European REACH regulations (EC 1907/2006).
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
Phosphatase and tensin homolog (PTEN) is a 402 AA protein that is expressed ubiquitously in the body. The main function of PTEN is to dephosphorylate phosphatidylinositol 3,4,5-triphosphate whereby resulting in the inhibition of the AKT signaling pathway; a pathway necessary for cell survival. Through this interaction PTEN was determined to play a crucial role in tumor suppression. In cancers like prostate, endometrial, lung and breast, PTEN expression is commonly lost or highly reduced. From the established connections between PTEN and cancer, PTEN is a highly sought after cancer biomarker. The PTEN AlphaLISA detection kit allows for the detection of PTEN in tissues homogenates and cell lysates.
AlphaLISA technology allows the detection of molecules of interest in a no-wash, highly sensitive, quantitative assay. In an AlphaLISA assay, a biotinylated anti-analyte antibody binds to the Streptavidin-coated Donor beads while another anti-analyte antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads causes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
|Assay Target Class||Protein|
|Experimental Type||In vitro|
|Shipping Condition||Blue Ice|
|Unit Size||5,000 assay points|
The introduction of enzyme-linked immunosorbent assays (ELISAs) in the early 1970’s offered researchers a non-radiometric immunoassay platform without compromising sensitivity. Over the last 50 years scientists have made huge strides in disease research and drug discovery and a demand for greater assay throughput and sensitivity has evolved. In response, more robust immunoassays have been developed to address some of the limitations of the standard, colorimetric ELISA.
Find out about the most common limitations of traditional ELISAs and how different ELISA alternative technologies address these limitations.